Skip to main content
Premium Trial:

Request an Annual Quote

ArcticDx Licenses Colorectal Cancer Biomarker IP from UK's CRT

NEW YORK (GenomeWeb News) – Cancer Research Technology, the technology commercialization arm of Cancer Research UK, said today that it will license certain intellectual property related to colorectal cancer risk assessment to the molecular diagnostics company ArcticDx.
Under the non-exclusive license agreement, ArcticDx will pay CRT an upfront payment and royalties from any sales of the biomarker-based test it plans to develop using the technology.
The test, called Colo Risk, is being developed to identify people who may be at higher risk for bowel cancer. ArcticDx CEO Greg Hines said the saliva-based test should be commercially available by the end of 2008.
The agreement will allow “some results” from Cancer Research UK-funded genome-wide association studies to be integrated into Colo Risk, CRT said, adding that these studies were “the first” to identify common SNPs that increase bowel cancer risk.

The Scan

LINE-1 Linked to Premature Aging Conditions

Researchers report in Science Translational Medicine that the accumulation of LINE-1 RNA contributes to premature aging conditions and that symptoms can be improved by targeting them.

Team Presents Cattle Genotype-Tissue Expression Atlas

Using RNA sequences representing thousands of cattle samples, researchers looked at relationships between cattle genotype and tissue expression in Nature Genetics.

Researchers Map Recombination in Khoe-San Population

With whole-genome sequences for dozens of individuals from the Nama population, researchers saw in Genome Biology fine-scale recombination patterns that clustered outside of other populations.

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.